Duyuru • Jun 29
Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C On June 27, 2025, Titan Pharmaceuticals, Inc. closed the transaction. Duyuru • Apr 24
Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025 Titan Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2025. Location: offices of olshan frome wolosky llp, located at 1325 avenue of the americas, 15th floor, new york 10019, new york, United States Duyuru • Jan 09
Titan Pharmaceuticals Receives Nasdaq Non-Compliance Notice Regarding Listing Rules 5620(a) and 5810(c)(2)(G) On January 3, 2025, Titan Pharmaceuticals, Inc. (the Company") received a notice (the Notice") from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (Nasdaq") that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2023 fiscal year end. The Notice has no immediate effect on the Company's listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may be granted an exception of up to 180 calendar days from the date of its December 31, 2024 fiscal year end, or until June 30, 2025, to regain compliance. The Company's failure to regain compliance with standards for continued listing would result in the ultimate de-listing of its common stock from Nasdaq. In response to the Notice, the Company intends to schedule an annual meeting of shareholders and to submit a plan designed to regain compliance in accordance with the requirements of the Notice and the Nasdaq listing standards. Duyuru • Nov 28
Titan Pharmaceuticals Announces Receipt of Notice from Nasdaq Titan Pharmaceuticals, Inc. reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q3 Form 10-Q”) in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq may grant an exception of up to 180 calendar days from the due date of the Third Quarter Form 10-Q, or until May 19, 2025, to regain compliance. In response to the Notice, the Company is working to file the Third Quarter Form 10-Q as soon as possible in order to regain compliance with the Listing Rule. However, if the Company does not submit the Third Quarter Form 10-Q by January 21, 2025, the Company will submit a plan by such date to Nasdaq that outlines, as definitively as possible, the steps the Company will take to promptly file the Third Quarter Form 10-Q. Additionally, on November 25, 2024, the Company received a notice (the “5605 Notice”) from Nasdaq advising the Company that, following the appointment of Brynner Chiam as Acting Principal Executive Officer and Acting Principal Financial Officer of the Company on November 6, 2024, the Company no longer complies with Nasdaq’s audit committee requirements as set in Listing Rule 5605 (“Rule 5605”). Nasdaq advised that consistent with Listing Rule 5605(c)(4), Nasdaq will provide the Company with a cure period in order to regain compliance with Rule 5605: (i) until the earlier of the Company’s next annual shareholders’ meeting or November 6, 2025; or (ii) if the next annual shareholders’ meeting is held before May 5, 2025, then the Company must evidence compliance no later than May 5, 2025. The Company intends to appoint an additional independent director to the Board of Directors and the Audit Committee prior to the end of the cure periods. Duyuru • Nov 16
Titan Pharmaceuticals, Inc. announced delayed 10-Q filing On 11/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Oct 25
Titan Pharmaceuticals, Inc. Announces Resignation of Dato’ Seow Gim Shen as Chairman of the Board On October 24, 2024, Dato’ Seow Gim Shen notified the Board of Directors of Titan Pharmaceuticals, Inc. of his decision to resign as Chairman of the Board of the Company. Mr. Shen indicated that his decision to resign was for personal reasons and not as a result of any disagreement with the Board or the Company’s management on any matter relating to the Company’s operations, policies or practices. The Company has launched a search to identify a suitable replacement for Mr. Shen. The Company anticipates that the resignation of Mr. Shen will not impact the previously announced business combination with KE Sdn. Bhd. currently being pursued by the Company. Duyuru • Aug 20
Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction. Ke Sdn. Bhd. entered into an agreement to acquire Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $21.6 million in a reverse merger transaction on August 19, 2024. Upon completion of the merger, the existing security holders of Ke Sdn. Bhd. ("KE") and Titan (excluding The Sire Group Ltd. and current Titan directors and officers) expect to own approximately 86.7% and 13.3%, respectively, of the outstanding shares of the combined company. It is expected that Dato’ Seow Gim Shen will own 48.9% of the outstanding shares of the combined company following the merger. Completion of the merger is subject to the approval of the merger by Titan’s stockholders, the registration statement shall have become effective, shares to be issued in connection with the transaction shall have been approved for listing on Nasdaq and satisfaction or waiver of other customary conditions. The agreement was unanimously approved by Titan’s board of directors. KE board of directors also approved the transaction. Kenneth Schlesinger and Claudia Dubon of Olshan Frome Wolosky LLP acted as legal advisor to Titan. Mitchell S. Nussbaum of Loeb & Loeb LLP acted as legal advisor to KE. Duyuru • Aug 16
Titan Pharmaceuticals, Inc. announced delayed 10-Q filing On 08/15/2024, Titan Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Duyuru • Apr 27
Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million. Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.
Security Name: Common Stock
Security Type: Common Stock Duyuru • Jan 19
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024 Titan Pharmaceuticals, Inc. announced that on January 11, 2024, Brian Crowley gave notice of his resignation as Senior Vice President, Finance and Administration of the company, effective February 2, 2024. Mr. Crowley served as the Company’s principal accounting officer. The board of directors has initiated a search process for a new principal accounting officer. Mr. Crowley will continue to assist the Company through February 2, 2024 in order to ensure a successful transition. Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022) Third quarter 2023 results: US$0.023 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$338.0k (loss narrowed 87% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Board Change • Nov 01
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. President, COO & Director Kate Beebe-DeVarney is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Sep 21
Titan Pharmaceuticals, Inc. Announces Board Resignations Titan Pharmaceuticals, Inc. announced that the pursuant to the Purchase Agreement, David Lazar and Peter Chasey submitted their resignations from the Company’s Board of Directors, which resignations are effective immediately upon the appointment of two replacement directors to fill the vacancies. The resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices. Mr. Lazar will remain with the Company as Chief Executive Officer. Reported Earnings • Aug 16
Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022) Second quarter 2023 results: US$0.11 loss per share (improved from US$0.18 loss in 2Q 2022). Revenue: US$83.0k (down 45% from 2Q 2022). Net loss: US$1.59m (loss narrowed 36% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings. Duyuru • Jul 29
Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million. Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million on July 27, 2023. Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to Titan of up to $50 million on future net sales of the products. Titan would also receive single digit royalties on future net sales of the products. Additionally, Fedson will assume all liabilities related to a pending employment claim against Titan. The transaction is expected to close 10 days following signing of the Agreement. Duyuru • Jul 08
Titan Pharmaceuticals, Inc. Announces Board Changes On July 6, 2023, the Board of Directors of Titan Pharmaceuticals, Inc. held a meeting at which it determined that a majority of the Board is comprised of independent directors in accordance with Nasdaq Listing Rule 5605(b)(1)(A). The Board also determined the composition of the Board committees for the upcoming year. The committees of the Board will be constituted as follows: Audit Committee: David Natan (Chair), Eric Greenberg, Matthew McMurdo, Compensation Committee: Matthew McMurdo (Chair), Peter Chasey, David Natan and Nominating and Governance Committee: Avraham Ben-Tzvi (Chair), Peter Chasey, Eric Greenberg. New Risk • Jun 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.1m free cash flow). Negative equity (-US$312k). Revenue is less than US$1m (US$463k revenue). Market cap is less than US$10m (US$9.76m market cap). Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Duyuru • Jun 07
Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) On June 5, 2023, Titan Pharmaceuticals, Inc. received a letter (the “Extension Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it had been granted an additional 180-day period, or until October 2, 2023, to regain compliance with Nasdaq Listing Rule 5550(b)(1). As previously disclosed on April 11, 2023, the Company received a notice (the “Notice”) on April 5, 2023 from the Staff notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2022 (“2022 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000 (the “Stockholders’ Equity Requirement”). In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy the Stockholders’ Equity Requirement. The Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1) on May 22, 2023. Pursuant to the Extension Notice, the Company must demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) on or before October 2, 2023, by furnishing to the Securities and Exchange Commission (the “SEC”) and Nasdaq certain information and representations on a Current Report on Form 8-K, among other obligations. If, after submitting this information to the SEC and Nasdaq as described in the Extension Notice, the Company fails to evidence compliance with Nasdaq Listing Rule 5550(b)(1) upon filing its Form 10-K for the year ended December 31, 2023, the Company may be subject to delisting from Nasdaq. In the event the Company fails to regain compliance, Nasdaq will issue the Company a delisting notice, at which time the Company would have the right to a hearing before an independent panel. The hearing request would halt any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. Reported Earnings • May 18
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022) First quarter 2023 results: US$0.11 loss per share (improved from US$0.24 loss in 1Q 2022). Revenue: US$98.0k (down 49% from 1Q 2022). Net loss: US$1.68m (loss narrowed 34% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jan 28
Principal Executive Officer recently bought US$56k worth of stock On the 25th of January, David Lazar bought around 58k shares on-market at roughly US$0.98 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. David has been a buyer over the last 12 months, purchasing a net total of US$3.9m worth in shares. Board Change • Nov 17
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Jim McNab was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Board Change • Aug 20
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Jim McNab was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Aug 12
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021) Second quarter 2022 results: US$0.18 loss per share (down from US$0.17 loss in 2Q 2021). Revenue: US$150.0k (down 66% from 2Q 2021). Net loss: US$2.46m (loss widened 47% from 2Q 2021). Over the next year, revenue is expected to shrink by 87% compared to a 16% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Jul 09
Insider recently bought US$1.7m worth of stock On the 7th of July, David Lazar bought around 2m shares on-market at roughly US$0.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$3.8m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Jun 10
Insider recently bought US$348k worth of stock On the 8th of June, David Lazar bought around 752k shares on-market at roughly US$0.46 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$506k more in shares than they have sold in the last 12 months. Reported Earnings • May 18
First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021) First quarter 2022 results: US$0.24 loss per share (up from US$0.28 loss in 1Q 2021). Revenue: US$192.0k (down 72% from 1Q 2021). Net loss: US$2.54m (loss narrowed 3.8% from 1Q 2021). Recent Insider Transactions • Apr 27
Insider recently bought US$157k worth of stock On the 18th of April, David Lazar bought around 171k shares on-market at roughly US$0.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Mar 28
Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020) Full year 2021 results: US$0.90 loss per share. Revenue: US$1.53m (down 69% from FY 2020). Net loss: US$8.78m (loss widened 19% from FY 2020). Reported Earnings • Nov 21
Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$264.0k (down 74% from 3Q 2020). Net loss: US$1.92m (loss widened 32% from 3Q 2020). Reported Earnings • Aug 18
Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020) The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: US$445.0k (down 66% from 2Q 2020). Net loss: US$1.68m (loss narrowed 64% from 2Q 2020). Reported Earnings • May 19
First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020) The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: US$682.0k (down 49% from 1Q 2020). Net loss: US$2.64m (loss narrowed 53% from 1Q 2020). Is New 90 Day High Low • Mar 05
New 90-day low: US$2.88 The company is down 18% from its price of US$3.50 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.